<SEC-DOCUMENT>0001104659-21-010507.txt : 20210202
<SEC-HEADER>0001104659-21-010507.hdr.sgml : 20210202
<ACCEPTANCE-DATETIME>20210202070027
ACCESSION NUMBER:		0001104659-21-010507
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210202
FILED AS OF DATE:		20210202
DATE AS OF CHANGE:		20210202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		21578992

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm213031d3_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of February 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 001-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">FORM
20-F&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">YES&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &ldquo;Yes&rdquo; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; vertical-align: top; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 2, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86px; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release dated February 2, 2021 &ndash; Curevac Announces Closing of $450 million Follow-on Public Offering of Common Shares</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm213031d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm213031d3_ex99-1img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac Announces Closing of $450
million Follow-on Public Offering of Common Shares</b></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>T&Uuml;BINGEN,
Germany/ BOSTON, USA &ndash;February&nbsp;2, 2021</B> &ndash; CureVac N.V. </FONT>(Nasdaq: CVAC) <FONT STYLE="font-family: Times New Roman, Times, Serif">(&ldquo;CureVac&rdquo;
or the &ldquo;Company&rdquo;), a global biopharmaceutical company developing a new class of transformative medicines based on messenger
ribonucleic acid (&ldquo;mRNA&rdquo;), announced today the closing of its follow-on public offering of 5,000,000 common shares,
at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">BofA Securities, Jefferies and Evercore
ISI are acting as joint book-running managers for the offering. UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen&nbsp;&amp;
Co are acting as passive book running managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">A registration statement relating
to these securities was declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on January&nbsp;27, 2021.
The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained,
when available, for free by visiting EDGAR on the SEC website at <U>www.sec.gov</U>. Alternatively, copies of the final prospectus,
when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street,
3rd Floor, Charlotte, NC 28255-0001, by telephone at (800) 299-1322 or by email at <U>dg.prospectus_requests@bofa.com</U>; Jefferies
LLC, Attention:&nbsp;Equity Syndicate Prospectus Department,&nbsp;520 Madison Avenue, 2nd Floor,&nbsp;New York, NY&nbsp;10022,
by telephone at (877) 821-7388 or by email at&nbsp;<U>Prospectus_Department@Jefferies.com</U>; and Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by telephone at (888) 474 0200, or by email
at <U>ecm.prospectus@evercore.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release shall not constitute
an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">CureVac is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the
versatile biological molecule for medical purposes. The principle of CureVac&rsquo;s proprietary technology is the use of non-chemically
modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.
Based on its proprietary technology, the company has built a deep clinical pipeline across the areas of prophylactic vaccines,
cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York
Nasdaq in August&nbsp;2020. It is headquartered in T&uuml;bingen, Germany, and employs more than 500 people at its sites in T&uuml;bingen,
Frankfurt, and Boston, USA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>CureVac Investor Relation Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Dr.&nbsp;Sarah Fakih, Vice President
Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">T: +49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>CureVac Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Thorsten Sch&uuml;ller, Vice President
Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">T: +49 7071 9883-1577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>thorsten.schueller@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CureVac&rsquo;s Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information set forth herein does not purport to be complete
or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless
stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances
create an implication that the information contained herein is correct as of any time after such date or that information will
be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains statements that constitute &ldquo;forward
looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including
statements that express the Company&rsquo;s opinions, expectations, beliefs, plans, objectives, assumptions or projections CureVac
regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion
of the company&rsquo;s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such
forward-looking statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
 &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative
of these terms or similar expressions. Forward looking statements are based on management&rsquo;s current beliefs and assumptions
and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company&rsquo;s
performance, and you should not place undue reliance on such statements.&nbsp; Forward-looking statements are subject to many risks,
uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility
in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical
trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability
to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition and consolidation in the company&rsquo;s industry, the effects
of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability to manage growth, reliance on key personnel,
reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due
to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s control and
could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included
in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events
or developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&rsquo;s
reports and documents filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC). You may get these documents by visiting
EDGAR on the&nbsp;SEC&nbsp;website at&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm213031d3_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm213031d3_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  T ),# 2(  A$! Q$!_\0
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M&G^;?P,^$_QB_P"%4_MZ>._&'PTUCP-K'[1NN?$SQ-X!^'.IWVEZIXT%A?\
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MM#+LHRO 4*.7Y9A)8C%8E8>FZ^.Q>)QF(K3@4445X9]X%%%% !1110 4444
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M%3QAXR\)ZOK_ .U#X$/B?XB:9HG@'4])\-:%>W'CJ+Q[P7XI_:L^+OQ@\/\
MQ6^&GP_\*^);RX^#WB?X3:5^T?\ &G]FOX[?LC^'_@W=7_Q0TSQ1\0--U?\
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9LEWJ]Y;3:G?M-?7=S-)]WT44 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
